Search
Rolapitant
go.drugbank.com/drugs/DB09291ApprovedInvestigationalNeurokinin-1 is also known as Tachykinin Receptor 1 (TACR1), Neurokinin 1 Receptor (NK1R), and Substance P Receptor (SPR). … Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and
Categories: Neurokinin-1 Receptor Antagonists, Substance P/Neurokinin-1 Receptor AntagonistMethyl nicotinate
go.drugbank.com/drugs/DB13882ApprovedMethyl nicotinate is the methyl ester of [DB00627] that is used as an active ingredient as a rubefacient in over-the-counter topical preparations indicated for muscle and joint pain. … The action of methyl nicotinate as a rubefacient is thought to involve peripheral vasodilation.
Caprylic acid
go.drugbank.com/drugs/DB04519ApprovedInvestigationalWithdrawnIt is an oily liquid with a slightly unpleasant rancid-like smell that is minimally soluble in water. … Caprylic acid is an eight-carbon chain fatty acid, also known systematically as octanoic acid. It is found naturally in coconuts and breast milk.
Anecortave acetate
go.drugbank.com/drugs/DB05288InvestigationalAnecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.
Ensifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationalEnsifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be
Synonyms: 2-(9,10-DIMETHOXY-4-OXO-2-(2,4,6-TRIMETHYLPHENYL)IMINO-6,7-DIHYDROPYRIMIDO(6,1-A)ISOQUINOLIN-3-YL)ETHYLUREA, N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREAStannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities [A32700].
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalMitapivat is a novel, first-in-class pyruvate kinase activator. It works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading
Aclidinium
go.drugbank.com/drugs/DB08897ApprovedAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigational[L52705] In December 2025, the FDA approved an additional indication for generalized myasthenia gravis. [L54838] … [A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19.
Safrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnSafrazine is a member of the hydrazine family with non-selective and irreversible inhibitor effects against monoamine oxidases. In 1960, it was used as an antidepressant but it is now discontinued.